이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

ProPhase Labs 배당금

배당금 기준 확인 0/6

ProPhase Labs 현재 배당금을 지급하지 않습니다.

주요 정보

배당 수익률

지급 비율

업계 평균 수익률	2.2%
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
주당 순이익	-US$1.24
3년 후 배당 수익률 예측	n/a

최근 배당금 업데이트

Recent updates

Does This Valuation Of ProPhase Labs, Inc. (NASDAQ:PRPH) Imply Investors Are Overpaying?

Mar 04

ProPhase Labs, Inc.'s (NASDAQ:PRPH) Business And Shares Still Trailing The Industry

Jan 09

ProPhase Labs, Inc. (NASDAQ:PRPH) Shares Could Be 28% Above Their Intrinsic Value Estimate

Sep 21

Here's Why ProPhase Labs (NASDAQ:PRPH) Can Afford Some Debt

Aug 11

We Ran A Stock Scan For Earnings Growth And ProPhase Labs (NASDAQ:PRPH) Passed With Ease

Apr 07

ProPhase Labs to license two investigational cancer compounds from Global BioLife

Jul 21

ProPhase Labs: A Stellar Quarter And Another Special Dividend

May 16

ProPhase Labs (NASDAQ:PRPH) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Apr 08

ProPhase Labs (NASDAQ:PRPH) Is Using Debt Safely

Mar 23

Rock star Growth Puts ProPhase Labs (NASDAQ:PRPH) In A Position To Use Debt

Nov 30

As Employer Vaccine Mandates Fail, Prophase Labs Could Benefit

Oct 20

Calculating The Fair Value Of ProPhase Labs, Inc. (NASDAQ:PRPH)

Jul 22

ProPhase Labs Is A Potential Pure Play On Worries About The Delta And Delta Plus Covid-19 Variants

Jun 28

Here's Why Shareholders May Consider Paying ProPhase Labs, Inc.'s (NASDAQ:PRPH) CEO A Little More

May 14

ProPhase Labs partners with Dutchess County New York to provide COVID-19 testing

May 06

A Look At The Intrinsic Value Of ProPhase Labs, Inc. (NASDAQ:PRPH)

Apr 12

ProPhase Labs opens Covid testing facility in New York

Jan 29

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 PRPH 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: PRPH 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

ProPhase Labs 시장 대비 배당 수익률

PRPH 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (PRPH)	0%
시장 하위 25% (US)	1.5%
시장 상위 25% (US)	4.7%
업계 평균 (Pharmaceuticals)	2.2%
3년 후 애널리스트 예측 (PRPH)	n/a

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 PRPH 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 PRPH 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: PRPH US 시장에서 주목할만한 배당금을 지급하지 않습니다.

주주에 대한 현금 배당금

현금 흐름 범위: PRPH 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

ProPhase Labs 배당금

배당금 기준 확인 0/6

주요 정보

최근 배당금 업데이트

Upcoming dividend of US$0.30 per share

ProPhase Labs, Inc. Declares Special Cash Dividend, Payable June 3, 2022

Upcoming dividend of US$0.30 per share

ProPhase Labs, Inc. Declares Special Cash Dividend, Payable on March 10, 2022

Upcoming dividend of US$0.30 per share

Prophase Labs, Inc. Declares Special Cash Dividend on Its Common Stock, Payable on June 3, 2021

Recent updates

Price target decreased by 7.5% to US$18.50

Insufficient new directors

ProPhase Labs, Inc., Annual General Meeting, Jun 20, 2024

ProPhase Labs, Inc. to Report Q1, 2024 Results on May 09, 2024

ProPhase Labs, Inc. Unveils Project ZenQ-AI

ProPhase Labs, Inc. announced delayed annual 10-K filing

ProPhase Labs, Inc. to Report Fiscal Year 2023 Results on Mar 15, 2024

Does This Valuation Of ProPhase Labs, Inc. (NASDAQ:PRPH) Imply Investors Are Overpaying?

Prophase Labs, Inc. Announces Important Developments in the Company’s Efforts to Commercialize Its Novel Be-Smart Esophageal Cancer Diagnostic Test

ProPhase Labs, Inc. Announces Preliminary Positive Results for Dietary Supplement Equivir

ProPhase Labs, Inc.'s (NASDAQ:PRPH) Business And Shares Still Trailing The Industry

Consensus revenue estimates fall by 16%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

ProPhase Labs, Inc. to Report Q3, 2023 Results on Nov 09, 2023

ProPhase Labs, Inc. (NASDAQ:PRPH) Shares Could Be 28% Above Their Intrinsic Value Estimate

Consensus EPS estimates fall by 46%

New minor risk - Market cap size

Here's Why ProPhase Labs (NASDAQ:PRPH) Can Afford Some Debt

First quarter 2023 earnings released: EPS: US$0.033 (vs US$0.81 in 1Q 2022)

Investor sentiment deteriorates as stock falls 15%

ProPhase Labs, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Investor sentiment deteriorates as stock falls 17%

ProPhase Labs, Inc Provides an Update Regarding Its Progress and Development Strategy for Linebacker-1

ProPhase Labs, Inc Provides an Update Regarding Its Progress and Development Strategy for Linebacker-1

Consensus estimates of losses per share improve by 19%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

ProPhase Labs, Inc. to Report Q1, 2023 Results on May 11, 2023

Investor sentiment improves as stock rises 18%

Price target increased by 13% to US$17.00

We Ran A Stock Scan For Earnings Growth And ProPhase Labs (NASDAQ:PRPH) Passed With Ease

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improves as stock rises 17%

ProPhase Labs, Inc. Provides Update on Linebacker-1 Cancer Co-Therapy Program and Outlines Development Strategy

Chairman & CEO exercised options and sold US$2.0m worth of stock

ProPhase Labs (NASDAQ:PRPH) Seems To Use Debt Quite Sensibly

Chairman & CEO exercised options and sold US$2.8m worth of stock

ProPhase Labs, Inc. (NasdaqCM:PRPH) acquired World-wide exclusive rights to Stella’s BE-Smart Esophageal Pre-Cancer diagnostic screening test from Stella Diagnostics Inc. (OTCPK:SLDX) for $4.6 million.

ProPhase Labs, Inc. Announces Executive Changes

ProPhase Labs, Inc. (NasdaqCM:PRPH) entered into an asset purchase agreement to acquire World-wide exclusive rights to Stella’s BE-Smart Esophageal Pre-Cancer diagnostic screening test from Stella Diagnostics Inc. (OTCPK:SLDX) for approximately $4.5 million.

Consensus forecasts updated

Insufficient new directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 23% undervalued after recent price drop

ProPhase Labs, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Investor sentiment improved over the past week

Chairman & CEO exercised options and sold US$3.1m worth of stock

ProPhase Labs: Small Cap Stock With Strong Fundamentals And Growth Potential

ProPhase Labs, Inc. Announces Resignation of Bill White as Chief Financial Officer

Consensus EPS estimates increase by 49%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

ProPhase Labs Q2 2022 Earnings Preview

ProPhase Labs, Inc. to Report Q2, 2022 Results on Aug 11, 2022

ProPhase Labs, Inc. (NasdaqCM:PRPH) announces an Equity Buyback for $6 million worth of its shares.

We Think ProPhase Labs (NASDAQ:PRPH) Can Stay On Top Of Its Debt

Investor sentiment deteriorated over the past week

ProPhase Labs to license two investigational cancer compounds from Global BioLife

Price target increased to US$14.50

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Insufficient new directors

Chairman & CEO exercised options and sold US$1.8m worth of stock

Investor sentiment improved over the past week

Price target decreased to US$13.00

Upcoming dividend of US$0.30 per share

ProPhase Labs: A Stellar Quarter And Another Special Dividend

ProPhase Labs, Inc. Declares Special Cash Dividend, Payable June 3, 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

ProPhase Labs, Inc. Announces Chief Financial Officer Changes with Effect from May 23, 2022

ProPhase Labs, Inc. to Report Q1, 2022 Results on May 13, 2022